Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

RO Clinical Boards > Thoracic > Flashcards

Thoracic Flashcards

1
Q

What is 2L chemo for SCLC

A

topotecan

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

NCCN guidelines for 2L treatment of ES-SCLC

A

If relapse <6 months post platinum, preferred regimen is topotecan, lurbinectidin or clinical trial, ipi/nivo is classified as other

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Number of cases of lung cancer per year

A

220000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What percentage of cases is SCLC

A

15%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Of the patients diagnosed with SCLC what share have LS

A

30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Prognostic factors for LS-SCLC

A
  1. age

2. gender

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Prognostic factors for ES-SCLC

A 
age
KPS
gender
# met sites
baseline Cr
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Markers positive for SCLC

A

synaptophysin
chromogranin A
CD56

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Treatment for LS-SCLC

A

concurrent chemoRT

cis-etoposide x 4 cycles with RT to 45 Gy in 1.5 Gy BID

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Dose of cisplatin for SCLC

A

80 mg/m2 day 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Dose of etoposide for SCLC

A

100 mg/m2 day 1,2,3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How often are cycles of cis-etop given

A

q3 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is OS for chemoRT for LS-SCLC

A

4 year OS of 30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pignon meta-analysis compared

A

RT alone vs. CRT for LS-SCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Findings of Pignon

A

CRT 3 year OS of 14% vs. 9% RT alone so absolute OS benefit of 5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is absolute OS benefit for CRT over RT

A

5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Per Pignon meta analysis which group benefited more

A

younger pts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Meta analysis showed that max benefit occurs when RT starts by week X of chemo

A

9

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

CONVERT trial design

A

Phase III of LS-SCLC randomized to

  1. 66/33 + cis etop 4-6 cycles
  2. 45/30 BID + cis etop 4-6
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Findings of CONVERT

A

Failed to show superiority of QD vs. BID and stated BID should remain SC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

CONVERT toxicity differences

A

No differences between arms in G3-4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

For CONVERT trial when did RT start

A

cycle 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

V20 goal for SCLC

A

<30-40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Mean lung dose goal

A

<20 Gy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Esophagus mean dose goal

A

<34 Gy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Spinal cord dose max goal

A

<36-37 Gy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

SCLC Turissi volumes

A

GTV + 1.5 cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What is the first line regimen for ES-SCLC

A

Carbo+Etoposide+Atezolizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

OS in IMPOWER133 trial

A

Atezo: 12.3 months

No atezo: 10 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

CREST (Slotman) trial for ES-SCLC design

A

RCT of 4-6 cycles of EP –> any response

  1. thoracic RT + PCI
  2. PCI alone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Dose of thoracic RT used on Slotman trial

A

30/10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Outcome of Slotman trial

A

Improved OS at 2 years
chest RT: 13%
no RT: 3%
Improved PFS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Chest volumes included on Slotman trial

A

Post chemo tumor + 1.5 cm

Pre chemo nodes (even if CR)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Lung constraint on Slotman trial

A

V20 < 35%

Defined lung as lung - PTV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

When should PCI be offered to patients

A

3-6 weeks after completion of chemo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Auperin meta analysis

A

Compared PCI vs. no PCI for patients with LS-SCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Results of Auperin meta-analysis

A

5% OS benefit at 3 years for patients who had PCI (20% v. 15%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Dose of PCI

A

25/10 (studies of 36 Gy no better)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Slotman ES-SCLC PCI study

A

Any response to chemo randomized to

  1. PCI (20-30 Gy)
  2. no PCI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Slotman finding

A

1 year OS
27% with PCI, 13% without PCI
Brain met risk
15% (PCI) –> 40% (no PCI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Any additional tox with PCI

A

did not affect global health score

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Criticism of Slotman study

A

no pre PCI brain imaging unless symptomatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Japanese PCI study

A

ES-SCLC with any response to chemo –> no brain mets on MRI –> randomized to

  1. PCI (25/10)
  2. no PCI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Results of PCI/no PCI OS

A

PCI: median of 11.6 months

No PCI: 13.7 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Rate of BM at 12 months without PCI

A

60% no PCI

33% PCI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Reduction in lung cancer specific mortality with low dose CT annually

A

20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

What proportion of NSCLC has EGFR mutation

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

What subtypes more likely to spread to brain?

A

adenocarcinoma, large cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

PET false negative rate for mediastinum

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Chamberlain procedure is needed to sample which stations

A

5, 6

Can also get 4, 7

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Level 5 nodes aka

A

AP window

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Optimal treatment of stage I NSCLC

A

lobectomy

MLND

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Can consider SBRT for lesions < X mm

A

5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Which factors are utilized to determine if patient is surgical candidate

A

FEV1

DLCO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

5 year OS with surgery alone for stage I

A

80%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

RTOG 0236 for peripheral tumors dose

A

20 x 3 to PTV but was actually 18 x 3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

What was the local control on 0236

A

90% ar 3 years, 80% at 5 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

What was OS at 3 years for this study

A

55%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

What was GTV expansion on 0236

A

1 cm craniocaudal, 0.5 cm radially unless 4D and image guidance in which case 0.5 cm circumferentially

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

SPACE trial

A

Randomized patients to

  1. 66 / 3 SBRT
  2. 70 / 35 3DCRT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Results of SPACE

A

no diff in OS

Trend towards improved LC, higher QOL with SBRT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

pCR rate 10 weeks after SBRT

A

60%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

PORT meta analysis OS

A

7% survival DECREASE with PORT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

PORT meta analysis locoregional failure

A

24% decrease in LRR with PORT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

Possible explanation of PORT metaanalysi

A

Old techniques (Co)
Weird fractionations
Early stage patients included

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

SEER Data suggests PORT may be advantageous for pts with

A

pN2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

ANITA analysis

A

pN1 - harmed by adjuvant RT (unless no chemo)

pN2 - benefit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

Chemo regimens for adenocarcinoma

A
  1. Cis/Pemetrexed

2. Carbo/Taxol +/- Bev

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

Chemo regimen for SCC

A

cis/etoposide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

When should adjuvant chemo be given

A

stage I - maybe if >4 cm

stage II/III yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

Mgmt of superior sulcus tumors

A

ChemoRT –> surgical resection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

SWOG 9416 trial design

A

2 cycles of cis-etoposide –> 45 Gy / 1.8 Gy

Additional RT to 60 Gy if unresectable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

What patients were included on Pancoast trial

A

T3-T4

N0-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

What percentage of patients underwent surgery

A

80%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

What were the surgical advantages of preop CRT

A

94% R0
29% CR
36% minimal microscopic residual

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

Auperin meta analysis for locally advanced concluded that concurrent CRT had X% OS advantage

A

5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

RTOG 0617

A

RCT of two dosing schedules

  1. 60/30
  2. 74/37
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

What chemo was used on 0617

A

Concurrent weekly carbo-taxol
Carbo AUC 2
Taxol 45 mg/2
then consolidation carbo-taxol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

Heart constraint on 0617

A

V60 < 1/3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

What heart dosimetric metric was identified as prognostic

A

Cardiac V50

V40 as well

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

Findings of 0617

A

high dose associated with poorer survival and control

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

Benefit of IMRT on 0617

A

IMRT had less G3+ pneumonitis

Associated with lower heart dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

Factors associated with improved OS on 0617

A 
60 Gy
Smaller PTV volume
Lower heart V5
Max esophagitis grade
Higher institutional accrual
Non-LLL or central location
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

PACIFIC trial design

A

ChemoRT to 60 Gy

Randomized to get durvalumab q2w for up to a year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

When do patients start durvalumab

A

1-42 days post CRT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

12 month PFS benefit for durva

A

durva: 55%
placebo: 35%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

Other endpoints improved with durva

A

Response rate
Duration of response
Time to death or distant mets

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

Preferred systemic therapy option for M1 disease

A

PDL1 > 50% - pembro

PDL1 < 50% - chemo+pembro

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

RTOG 0937 [PCI + PCI + consolidative RT to intrathoracic/extracranial mets for ES-SCLC] dose to thoracic/extracranial disease

A

45 Gy in 15

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

RTOG 0937 [PCI + PCI + consolidative RT to intrathoracic/extracranial mets for ES-SCLC] OS findings

A

No difference at 1 year [60% vs. 51%, NSS]

But oligometastatic ES-SCLC outcomes similar to LS-SCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
91
Q

RTOG 0937 [PCI + PCI + consolidative RT to intrathoracic/extracranial mets for ES-SCLC] time to progression

A

Favored consolidation arm and most pts on PCI only arm failed in initially involved sites

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
92
Q

How was CONVERT trial designed?

A

To show superiority of 66 Gy QD vs. 45 BID

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
93
Q

How many cycles of chemo on CONVERT?

A

4-6 cycles of cis-etoposide q3w

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
94
Q

When did RT start on CONVERT

A

day 22 (with cycle 2)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
95
Q

Design of RTOG 0617

A

2x2 factorial study randomized to

  1. 60 Gy
  2. 74 Gy
  3. 60 Gy + Cetuximab
  4. 74 Gy + Cetuximab
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
96
Q

Patients included on 0617

A

Unresectable stage III, no SCV or contralateral hilar nodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
97
Q

Chemo used on 0617

A

concurrent and adjuvant
concurrent carbo (AUC 2) and paclitaxel (45 mg/m2) weekly
adjuvant 2 cycles of carbo (AUC 6) and paclitaxel (200 mg/m2) q3w

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
98
Q

Dose of cetuximab on 0617

A

400 mg/m2 (day 1) –> 250 (weekly)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
99
Q

Median OS for 60 Gy arm

A

29 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
100
Q

Median OS for 74 Gy arm

A

20 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
101
Q

Median OS for cetux vs. no cetux

A

25 vs. 24 months (NSS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
102
Q

1 year LF for 60 vs 74 Gy arm

A

16% vs. 25% (NSS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
103
Q

0617 differences in toxicity by dose

A

No differences between G3+ by dose level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
104
Q

0617 differences in toxicity by cetux/no cetux

A

86% for cetux vs. 70% for no cetux

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
105
Q

What tox was worse with 74 Gy

A

severe esophagitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
106
Q

From 0617 factors associated with OS

A
  1. 60 Gy
  2. Max esophagitis grade
  3. PTV size
  4. Heart V5 and V30
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
107
Q

AP/PA field border for hemithoracic RT for meso - superior

A

Top of T1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
108
Q

AP/PA field border for hemithoracic RT for meso - inferior

A

bottom of L2

109
Q

AP/PA field border for hemithoracic RT for meso - lateral

A

flash skin

110
Q

AP/PA field border for hemithoracic RT for meso - medial

A

if N+: 1.5-2 cm beyond contralateral vertebral body border

if N-: contralateral vertebral body border

111
Q

INT 0096 Turrisi study design

A

LS-SCLC randomized to either

  1. 45 Gy (1.8 daily)
  2. 45 Gy (1.5 BID)
112
Q

INT 0096 Turrisi study chemo used

A

cis: 60 mg/m2
etoposide: 120 mg/m2
q3w x 4 cycles

113
Q

5y OS results for INT 0096

A

Hyperfractionation 26%

Standard fractionation 16%

114
Q

CHISEL study design [TROG 09.02]

A

Stage I NSCLC (T1-2aN0) peripherally located randomized 2:1 to

  1. SBRT
  2. standard RT
115
Q

CHISEL results - LC

A

SBRT: 89%
Standard: 65%

116
Q

Median OS

A

SBRT 5 years

Standard: 3 years

117
Q

Conclusion of CHISEL

A

In patients with peripheral stage I NSCLC, SBRT resulted in superior tumor control and OS compared to standard RT

118
Q

When doing SBRT for large tumors, what was different from doing daily fx vs. QOD

A

Rate of G2+ toxicity

119
Q

Gomez study patients

A

Stage IV NSCLC
3 or fewer mets
No POD at 3 or more months after front line systemic therapy

120
Q

Gomez study design

A

RCT of

  1. Maintenance therapy or obs
  2. SBRT to all active disease sites
121
Q

Gomez study results - PFS

A

SBRT: 14 months

Systemic therapy: 4 months

122
Q

Gomez study results - OS

A

SBRT: 41 months
Systemic: 17 months

123
Q

On Gomez study any differences in tox

A

no significant G3+ differences

124
Q

SBRT dose for peripheral tumors

A

18 x 3

60/8 if >5 cm

125
Q

SBRT dose for central tumors

A

12.5 x 4
10 x 5
60/8

126
Q

SBRT dose for ultracentral tumors

A

60/8
65/10
70/10
Concurrent CRT

127
Q

Chest wall constraint for SBRT

A

V30 < 30 cc

128
Q

Lung constraint for SBRT

A

V20 < 25% (ipsi lung)

V20 < 12.5% (both lungs)

129
Q

PORT dose

A

50.4 Gy

10 Gy boost for + margin or ECE

130
Q

Indications for PORT

A

N2

Positive margin

131
Q

Conventional RT constraint for V20

A

<30-35%

132
Q

Conventional RT constraint for lung mean dose

A

20 Gy

133
Q

Conventional RT constraint for Heart V50

A

<25%

134
Q

Conventional RT constraint for Heart mean dose

A

20 Gy

135
Q

Conventional RT constraint for spinal cord Dmax

A

50 Gy

136
Q

Conventional RT constraint for esophagus mean

A

34 Gy

137
Q

Conventional RT constraint for Dmax esophagus

A

<105%

138
Q

Conventional RT constraint for esophagus V60

A

<17%

139
Q

Conventional RT constraint for brachial plexus

A

<66-69 Gy

140
Q

Where does brachial plexus run through

A

anterior and middle scalene

141
Q

Risk of RT pneumonitis is

A

5-15% 1-3 months post RT

142
Q

What does grade 2 pneumonitis require

A

steroids

143
Q

What does grade 3 pneumonitis require

A

oxygen

144
Q

Steroid dose for RT pneumonitis

A

60 mg pred x 2 weeks

Slow taper over 6-12 weeks

145
Q

T1 lung

A

<3 cm

146
Q

T1a lung

A

0-1

147
Q

T1b lung

A

1-2 cm

148
Q

T2 lung

A

3-5 cm

149
Q

T2a lung

A

3-4 cm

150
Q

T2b lung

A

4-5 cm

151
Q

T3 lung

A

Tumor 5-7
Invasion of chest wall, parietal pleura/pericardium
Two nodules in same lobe

152
Q

T4 lung

A

Tumor >7 cm
Invasion of heart, great vessels, diaphragm, trachea, carina, separate nodules in ipsilateral lobe different from primary

153
Q

N1 lung

A

Ipsi peribronchial or hilar node

154
Q

N2 lung

A

Ipsi mediastinal and/or subcarinal node

155
Q

N3 lung

A

Contralateral mediastinal
Contralateral hilar
Ipsi or contra SCV node

156
Q

M1a

A

Tumor nodules in contralateral lobe
Pleural or pericardial nodules
Malignant pleural/pericardial effusion

157
Q

Thymoma typically affects what chamber of mediastinum

A

anterior (most common tumor)

158
Q

Median age of patients with thymoma

A

older than 50

159
Q

What % of patients with myasthenia gravis have thymoma

A

10-15%

160
Q

What determines prognosis of thymoma

A

invasiveness

completeness of surgical resection

161
Q

Treatment of choice for thymoma

A

en bloc surgical resection

162
Q

Masaoka stage I

A

grossly and microscopically completely encapsulated

163
Q

Masaoka stage IIa

A

Microscopic transcapsular invasion

164
Q

Masaoka stage IIb

A

Macroscopic invasion into thymic or surrounding fatty tissue or grossly adherent to pleura/pericardium but not through

165
Q

Masaoka stage III

A

Macroscopic invasion into neighboring organ (pericardium, great vessel, lung)
invasion into pleura

166
Q

Masaoka stage IVa

A

Pleural or pericardial mets

167
Q

Masaoka stage IVb

A

lymphogenous or hematogenous mets

168
Q

What determines Masaoka stage

A

depth of invasion

169
Q

Which RO stage thymoma should get PORT

A

stage II-IV only if close margins (45-50)

170
Q

R1 resections should get what dose

A

54

171
Q

For R2 resections or unresectable

A

60-70 Gy to entire thymic bed often with concurrent cisplatin

172
Q

Stage I meso

A

pleura only

173
Q

Stage II meso

A

diaphragm or lung involvement

174
Q

Stage III meso

A

chest wall, potentially resectable

175
Q

Stage IV meso

A

unresectable

176
Q

What is the preferred surgical approach for meso

A

extrapleural pneumonectomy

177
Q

What is the other surgical option

A

pleurectomy/decortication

178
Q

Common preop dose

A

45 Gy

179
Q

Patients with borderline N2 nodes on PET should undergo

A

pathologic staging of mediastinum prior to committing to a treatment strategy

180
Q

What stage is N3 lung disease

A

T1-T2: IIIB

T3-T4: IIIC

181
Q

Which two veins converge to form SVC

A

Left brachiocephalic vein

Right brachiocephalic vein

182
Q

The brachiocephalic artery becomes the

A

R common carotid

R subclavian artery

183
Q

RTOG 0813 centrally located SBRT trial lung constraint V20

A

<10%

184
Q

RTOG 0813 centrally located SBRT trial lung constraint volume getting less than 12.5 Gy

A

> 1500 cc

185
Q

RTOG 9410 (Curran) sequential vs. concurrent CRT patients

A

medically or surgically inoperable stage II-IIIB

186
Q

9410 design

A

RCT of 3 arms

  1. Induction chemo –> RT cis/vinorelbine
  2. Concurrent ChemoRT (63 Gy), 1.8 x 25 then 2 x 9 cis/vinorelbine
  3. Concurrent Hyperfractionated CRT (69.6 Gy in BID fractions) with cis/etoposide
187
Q

Chemo used in 9410

A

Cisplatin 100 mg/m2 day 1/29

Vinorelbine 5 mg/m2 weekly x 5 weeks

188
Q

Survival conclusion from 9410

A

OS advantage for the two concurrent arms over the sequential

189
Q

Toxicity conclusion from 9410

A

Early toxicity was worse with concurrent (especially esophagitis) but late was similar

190
Q

T1c lung

A

2-3 cm

191
Q

Invasion of visceral pleura is what T stage

A

T2a

192
Q

Invasion of parietal pleura is what T stage

A

T3

193
Q

Mainstem bronchus invasion is what T stage

A

T2

194
Q

Atelectasis/obstructive pneumonitis extending to hilum is what T stage

A

T2

195
Q

Invasion of diaphragm is what stage

A

T4

196
Q

Chest wall invasion is what T stage

A

T3

197
Q

Superior sulcus tumor is what T stage

A

T3

198
Q

What paraneoplastic syndrome associated with lung SCC

A

PTHrP associated hyperCa

199
Q

What paraneoplastic syndrome associated with SCLC

A

Lambert-Eaton
cerebellar ataxia
SIADH

200
Q

Osimertinib improves DFS or death by what % post resection?

A

80%

201
Q

From ADAURA trial did osimertinib decrease rates of locoregional or distance recurrence?

A

Both

202
Q

FEV1 requirments for surgery

A

FEV1 < 40-50%

Predicted postop FEV1 <30%

203
Q

What is top risk for RFA of early stage lung cancer

A

pneumothorax

204
Q

Results from Slotman CREST trial

A

No difference in 1 year OS (primary outcome)
13% vs. 3% difference for 2 year OS
Improved PFS

205
Q

CALGB 39801 (Volkes trial) conclusion

A

No benefit for induction chemo –> chemoRT for nonoperable Stage III patients

206
Q

Albain 2009 research question

A

For patients with borderline IIIA disease, is there a benefit for induction chemoRT prior to resection vs. definitive chemoRT

207
Q

Albain conclusion

A

No difference in survival, possible benefit for those downstaged to require just lobectomy

208
Q

RTOG 9410 (Curran) research question

A

Is concurrent chemoRT superior to sequential chemo –> RT (yes!)

209
Q

At what dose should heart be blocked for meso treatment

A

19.8 Gy

210
Q

What structure is blocked for full meso treatment

A

stomacjh

211
Q

Median survival of stage I lung cancer without treatment

A

1 year

212
Q

On subgroup analysis from Albain neoadjuvant chemoRT trial found improved OS for which group

A

Pts who got lobectomy
Trimodality: 36%
ChemoRT: 18%

213
Q

KEYNOTE 189

A

Found that pemrbo + chemo increases PFS and OS in all PDL1 statuses

214
Q

What subgroup benefits most from pembro+chemo

A

PDL1 > 50% but all subgroups do benefit even PDL <1%

215
Q

Where are primary tracheal ACC usually located

A

proximal trachea
slow growth
late distant mets
possibility of perineural spread

216
Q

Patients with radiographically negative PET have X% chance of N2 disease on surgical staging

A

15%

217
Q

What tumors had higher risk of occult N2 disease

A

Central tumors
RUL
N1 disease on PET

218
Q

Which patients should get adjuvant chemo

A

I: if >4 cm

II/III: all

219
Q

T1 meso

A

ipsi parietal pleura

220
Q

T2 meso

A

ipsi parietal pleura with involvement of underlying lung or diaprhgammatic muscle

221
Q

T3 meso

A

locally advanced, potentially resectable

222
Q

T4 meso

A

unresectable

223
Q

N1 meso

A

ipsi hilar, mediastinal, IMN, peridiagrphrammaic, intercostal nodes

224
Q

N2 meso

A

contra mediastinal, ipsi/contra SCV

225
Q

Thymoma RT dose for gross residual disease

A

60-70

226
Q

Thymoma RT dose for involved margins

A

54 Gy

227
Q

Thymoma RT dose for clear/close margins

A

45-50

228
Q

5 year freedom from failure rate for unresected thymoma getting chemo –> 54 Gy

A

54%

229
Q

Appropriate CTV margin of adenocarcinoma

A

8mm

230
Q

Appropriate CTV margin of SCC

A

6mm

231
Q

Lambert eaton presentation

A

progressive muscle weakness of proximal lower extremities

232
Q

What is 1 year OS with PCI on ES-SCLC slotman study

A

27%

233
Q

What is 1 year OS without PCI on ES-SCLC slotman study

A

13%

234
Q

PACIFIC trial - how long did patients get durva

A

1 year

235
Q

PACIFIC trial 2 year OS with Durva

A

66%

236
Q

PACIFIC trial 2 year OS without Durva

A

56%

237
Q

PACIFIC trial PFS differences

A

17 vs. 6 months

238
Q

Subsets potentially benefitted more from durva

A

PDL1 > 25%

Starting durva within 2 weeks post CRT

239
Q

V20 goal for contralateral lung after extrapleural pneumonectomy using IMRT

A

<7%

240
Q

What levels should always be covered when doing PORT

A

level 7
ipsi level 4
level 5/6 for left sided N2 disease

241
Q

0617 V45 heart goal

A

<2/3

242
Q

0617 V60 heart goal

A

<1/3

243
Q

0617 V40 heart goal

A

<100%

244
Q

When should spinal cord be blocked when doing hemithoracic RT for meso

A

41.4

245
Q

Max dose to plexus for SBRT

A

D3cc < 6 x 5

246
Q

CONVERT trial median OS for 45 BID vs. 66 QD

A

30 months vs 25 months NSS

247
Q

What chemo given with CONVERT

A

cis-etoposide

248
Q

What is the preferred chemo regimen for mesothelioma

A

cis-pemetrexed +/- BEV

249
Q

What is preferred chemo regimen for thymoma

A

cis, doxorubicin, cyclophosphamide

250
Q

age range to get low dose CT

A

50-80

251
Q

pack year history minimum to get low dose CT

A

20

252
Q

smoking status to get low dose CT

A

active smoker or quit in past 15 years

253
Q

Expected 5 year OS after neoadjuvant CRT and R0 resection of superior sulcus tumor

A

54%

254
Q

Rate of severe toxicity for central tumors from Timmerman study

A

46%

255
Q

Rate of severe toxicity for peripheral tumors from Timmerman study

A

17%

256
Q

MTD of SBRT to ultracentral tumors from RTOG 0813 (Bezjak)

A

12 x 5

257
Q

What was DLT rate for this treatment dose

A

7.5%

258
Q

RTOG 0236 Timmerman study dose utilized

A

18 x 3

259
Q

RTOG 0236 Timmerman study max size

A

5 cm

260
Q

RTOG 0236 Timmerman study 3 year local control (primary tumor and involved lobe)

A

91%

261
Q

RTOG 0236 Timmerman study dose 3 year distant met rate

A

22%

262
Q

RTOG 0236 Timmerman study dose 3 year OS

A

56%

263
Q

RTOG 0236 Timmerman study dose 5 year local failure

A

7%

264
Q

RTOG 0236 Timmerman study dose 5 year local and involved lobe

A

20%

265
Q

RTOG 0236 Timmerman study dose 5 year OS

A

40%

266
Q

In Turrisi study, what was worse in BID treatment

A

Increased G3 esophagitis (27% vs. 11%)

267
Q

Rate of local failure after lobectomy on Ginsburg study

A

6%

268
Q

Rate of local failure after sublobar resection

A

18%

RO Clinical Boards (13 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions